Brth

Free trading of stocks, ETFs, and options refers to commissions for Webull Financial LLC self-directed individual cash or margin brokerage accounts and IRAs that trade U.S. listed securities via mobile devices, desktop or website products. A .55 per contract fee applies for certain index options and a .10 per contract fee applies for oversized option orders. Relevant regulatory and exchange fees may apply. Please refer to our Fee Schedule for more details.

Brth

Apologies, but your page or document does not exist.

• The page or document has been moved, deleted, or never existed.
• The link that brought you here was incorrect.
• If you typed in the address, you may have made an error.

Brth

Breathe BioMedical Inc. is a medical technology company. It is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breath analytics involves the collection, processing, and analysis of breath samples to identify biomarker patterns associated with specific diseases. It is developing a proprietary end-to-end breath analytics platform, the intended use of which is to enable breath testing for the detection of disease. Its platform technology combines three advanced technologies to sample, digitize and analyze breath with the potential to detect multiple diseases. Its spectrometer technology uses Cavity Ring-Down Spectroscopy (CRDS) to measure the volatile organic compounds (VOCs) in breath samples which are collected using its breath sampler device (SohnoXB). Spectrometer is designed to be very fast, permitting sample analysis down to parts-per-trillion levels.

Webull offers Breathe BioMedical Inc. stock information, including NASDAQ: BRTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRTH stock methods without spending real money on the virtual paper trading platform.

Download on the

Securities trading is offered to self-directed customers by Webull Financial LLC, a broker dealer registered with the Securities and Exchange Commission (SEC). Webull Financial LLC is a member of the Financial Industry Regulatory Authority (FINRA), Securities Investor Protection Corporation (SIPC), The New York Stock Exchange (NYSE), NASDAQ and Cboe EDGX Exchange, Inc (CBOE EDGX).

Webull Financial, LLC is a CFTC registered Futures Commission Merchant and NFA Member. Futures and futures options trading involves substantial risk and is not suitable for all investors. Please read the Risk Disclosure Statement and other relevant Futures Disclosures located at www.webull.com/fcm-disclosures prior to trading futures products. Futures accounts are not protected by the Securities Investor Protection Corporation (SIPC).

Advisory accounts and services are provided by Webull Advisors LLC (also known as «Webull Advisors»). Webull Advisors is an Investment Advisor registered with and regulated by the SEC under the Investment Advisors Act of 1940. Registration does not imply a level of skill or training. See additional information on the Disclosures webpage. Trades in your Webull Advisors account are executed by Webull Financial LLC.

Webull Financial LLC is a member of SIPC, which protects securities customers of its members up to $500,000 (including $250,000 in any cash awaiting reinvestment). An explanatory brochure is available upon request or at www.sipc.org. Webull Financial LLC’s clearing firm Apex Clearing Corp has purchased an additional insurance policy. The coverage limits provide protection for securities and cash up to an aggregate of $150 million, subject to maximum limits of $37.5 million for any one customer’s securities and $900,000 for any one customer’s cash. Similar to SIPC protection, this additional insurance does not protect against a loss in the market value of securities.

Options trading entails significant risk and is not appropriate for all investors. Option investors can rapidly lose the value of their investment in a short period of time and incur permanent loss by expiration date. Losses can potentially exceed the initial required deposit. You need to complete an options trading application and get approval on eligible accounts. Please read the Characteristics and Risks of Standardized Options before trading options.

All investments involve risk, and not all risks are suitable for every investor. The value of securities may fluctuate and as a result, clients may lose more than their original investment. The past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss in a down market. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing.

Diversification does not eliminate the risk of experiencing investment losses. Margin trading increases risk of loss and includes the possibility of a forced sale if account equity drops below required levels. Margin is not available in all account types. Margin trading privileges are subject to Webull Financial, LLC review and approval. Leverage carries a high level of risk and is not suitable for all investors. Greater leverage creates greater losses in the event of adverse market movements.

Investors should be aware that system response, execution price, speed, liquidity, market data, and account access times are affected by many factors, including market volatility, size and type of order, market conditions, system performance, and other factors. Market volatility, volume and system availability may delay account access and trade executions.

Free trading of stocks, ETFs, and options refers to commissions for Webull Financial LLC self-directed individual cash or margin brokerage accounts and IRAs that trade U.S. listed securities via mobile devices, desktop or website products. A .55 per contract fee applies for certain index options and a .10 per contract fee applies for oversized option orders. Relevant regulatory and exchange fees may apply. Please refer to our Fee Schedule for more details.

No content on the Webull Financial LLC website shall be considered as a recommendation or solicitation for the purchase or sale of securities, options, or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.

Canadian diagnostics developer Breathe BioMedical sets terms for $8 million US IPO

Breathe BioMedical, a Canadian medical technology company developing a breath test for breast cancer, announced terms for its IPO on Friday.

The Moncton, Canada-based company plans to raise $8 million by offering 1.6 million shares at a price range of $4 to $6. At the midpoint of the proposed range, Breathe BioMedical would command a fully diluted market value of $54 million.

Breathe BioMedical is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Over the next two years, the company has verification and validation studies, as well as a large multi-center clinical study planned to evaluate the safety and efficacy, for the various components of its Breast Cancer Breath Test. It is currently conducting a proof-of-concept study, for which data collection will be completed in 3Q24. Breathe BioMedical anticipates the completion of the components, the Breast Cancer Breath Test, and the verification and validation studies in 2025 with a pivotal trial in 2026 to support a marketing authorization application in the US in 2027, subject to discussion with the FDA.

Breathe BioMedical was founded in 2005 and plans to list on the Nasdaq under the symbol BRTH. Maxim Group LLC is the sole bookrunner on the deal.

Breathe BioMedical Filed Terms, Nasdaq: BRTH

Latest Trade: () First Day Return: Return from IPO:

Industry: Health Care

We are a medical technology company focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breathe BioMedical is in the development stage of our Breast Cancer Breath Test, as an adjunct to mammography screening in women with dense breast tissue. Over the next two years we have verification and validation studies planned for the components and the Breast Cancer Breath Test, as well as a large multi-center clinical study planned to evaluate the safety and efficacy of the Breast Cancer Breath Test, subject to discussions with regulatory authorities, and build our machine learning model for breast cancer. We are currently conducting a proof-of-concept study which is discussed in detail in the Business section, under the “Breast Cancer Breath Test” heading. Data collection will be completed in 3Q2024. Data analysis will follow. We anticipate the completion of the components, the Breast Cancer Breath Test, and the verification and validation studies in 2025 with a pivotal trial in 2026 to support a marketing authorization application in the U.S. in 2027, subject to discussion with the FDA. We expect this could lead to FDA approval for our Breast Cancer Breath Test by 2027. There is no guarantee that we will meet these development milestones or be granted marketing authorization by 2027, if at all.

more less

• Canadian diagnostics developer Breathe BioMedical increases share offering by 64% ahead of $13 million US IPO 07/26/24
• Canadian diagnostics developer Breathe BioMedical sets terms for $8 million US IPO 07/05/24
• US IPO Weekly Recap: Healthcare software leads $1.3 billion IPO week, even as Novelis calls off IPO 06/07/24

Canadian diagnostics developer Breathe BioMedical files for a $12 million dual listing in the US and Canada

Breathe BioMedical, a Canadian medical technology company developing a breath test for breast cancer, filed on Friday with the SEC to raise up to $12 million in an initial public offering. The company plans to concurrently list its shares in Canada, though it did not specify which exchange.

Breathe BioMedical is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Over the next two years, the company has verification and validation studies, as well as a large multi-center clinical study planned to evaluate the safety and efficacy, for the various components of its Breast Cancer Breath Test. It is currently conducting a proof-of-concept study, for which data collection will be completed in 3Q24. Breathe BioMedical anticipates the completion of the components, the Breast Cancer Breath Test, and the verification and validation studies in 2025 with a pivotal trial in 2026 to support a marketing authorization application in the US in 2027, subject to discussion with the FDA.

The Moncton, Canada-based company was founded in 2005 and plans to list on the Nasdaq under the symbol BRTH. Breathe BioMedical filed confidentially on March 4, 2024. Maxim Group LLC is the sole bookrunner on the deal. No pricing terms were disclosed.

Relevant Profile: BRTH
IPO PRO
Self Service

Track IPO Activity
with our
Easy to use Portal

Get your Free Trial

IPO Intelligence
for Institutional Investors

Powerful Pre-IPO Research
Trusted by Top
Investment Firms & Banks

Request your Free Trial

The Renaissance
IPO ETF

Get Exposure
to Unique
New Stocks

Click here for How to Invest

Bad title

The requested page title is invalid. It may be empty, contain unsupported characters, or include a non-local or incorrectly linked interwiki prefix. You may be able to locate the desired page by searching for its name (with the interwiki prefix, if any) in the search box.

Possible causes are:

• an attempt to load a URL such as https://en.wikipedia.org/wiki/| (the | character is unsupported);
• an attempt to load a URL pointing to a «non-local» interwiki page (usually those not run by the Wikimedia Foundation). For example, the URL https://en.wikipedia.org/wiki/meatball:WikiPedia will give this error, because the «meatball:» interwiki prefix is not marked as local in the interwiki table. Certain interwiki prefixes are marked as local in the table. For example, the URL https://en.wikipedia.org/wiki/meta:Main_Page can be used to load meta:Main_Page. All interlanguage prefixes are marked as local, and thus URLs such as https://en.wikipedia.org/wiki/fr:Accueil will work as expected. However, non-local interwiki pages can still be accessed by interwiki linking or by entering them in the search box. For example [[meatball:WikiPedia]] can be used on a page, like this: meatball:WikiPedia.

Retrieved from «https://en.wikipedia.org/wiki/Special:Badtitle»

• Privacy policy
• About Wikipedia
• Disclaimers
• Contact Wikipedia
• Code of Conduct
• Developers
• Statistics
• Cookie statement
• Mobile view

Canadian diagnostics developer Breathe BioMedical increases share offering by 64% ahead of $13 million US IPO

Breathe BioMedical, a Canadian medical technology company developing a breath test for breast cancer, raised the proposed deal size for its upcoming IPO on Friday.

The Moncton, Canada-based company now plans to raise $13 million by offering 2.6 million shares at a price range of $4 to $6. The company had previously filed to offer 1.6 million shares at the same range. At the revised deal size, Breathe BioMedical will raise 64% more in proceeds than previously anticipated and command a fully diluted market value of $59 million.

Breathe BioMedical is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Over the next two years, the company has verification and validation studies, as well as a large multi-center clinical study planned to evaluate the safety and efficacy, for the various components of its Breast Cancer Breath Test. It is currently conducting a proof-of-concept study, for which data collection will be completed in 3Q24. Breathe BioMedical anticipates the completion of the components, the Breast Cancer Breath Test, and the verification and validation studies in 2025 with a pivotal trial in 2026 to support a marketing authorization application in the US in 2027, subject to discussion with the FDA.

Breathe BioMedical was founded in 2005 and plans to list on the Nasdaq under the symbol BRTH. Maxim Group LLC is the sole bookrunner on the deal.

Brth

Apologies, but your page or document does not exist.

• The page or document has been moved, deleted, or never existed.
• The link that brought you here was incorrect.
• If you typed in the address, you may have made an error.

Brth

Apologies, but your page or document does not exist.

• The page or document has been moved, deleted, or never existed.
• The link that brought you here was incorrect.
• If you typed in the address, you may have made an error.

Источники:

https://www.oregon.gov/oha/PH/BIRTHDEATHCERTIFICATES/Pages/ContactCHS.aspx&rut=2895c66d0d110c24ed6c359ff5229867ecc54ec4e1ce7fa0595b83b72f4f17b9
https://www.webull.com/quote/nasdaq-brth&rut=4756b7b257d11d5622c1817da569c47fe7660eb800255b948e00ab92e7118bc3
https://www.renaissancecapital.com/IPO-Center/News/105559/Canadian-diagnostics-developer-Breathe-BioMedical-sets-terms-for-$8-million&rut=37966f935c32cdb371c8009177cb54089e8fcf0276257f27f190771b61878c16
https://www.renaissancecapital.com/Profile/BRTH/Breathe-BioMedical/IPO&rut=2f299810ba6d31b250a4ae56b7d297b08cb00ebdd7c6c6dc4d410b0ab0798ae4
https://www.renaissancecapital.com/IPO-Center/News/105101/Canadian-diagnostics-developer-Breathe-BioMedical-files-for-a-$12-million-d&rut=8916cf777c220f6d8cb4dd0d1b868a4a5f9ba32971f5445970e924d8a662232f
https://en.wikipedia.org/wiki/Birth_(American_Horror_Story)&rut=eb2cac3501434d5b20f3b266fe590294e988ebe965ec2bf0f67ccb18dc1c7a39
https://www.renaissancecapital.com/IPO-Center/News/105898/Canadian-diagnostics-developer-Breathe-BioMedical-increases-share-offering-&rut=187bd85fef3778c52943694751939bded2dbbc73ef063b598c958feff9ea49e8
https://www.oregon.gov/oha/PH/BIRTHDEATHCERTIFICATES/Pages/OrderBirthCertificate.aspx&rut=a2e4e8408a4699a207ed8d0e5fcfb2c230b5a36c07feb59a3f5510dcf2f10ba6
https://www.oregon.gov/oha/PH/BIRTHDEATHCERTIFICATES/Pages/index.aspx&rut=370c3b7d9aaf6301f6a03328484fd145536aa91a11af72068c0a4cbac9e132d9